Kezar Life Sciences files Form 25 to withdraw common stock

Kezar Life Sciences, Inc. submitted a Form 25 notification reflecting the removal/withdrawal of its common stock from listing and registration on the Nasdaq Stock Market LLC.

Rhea-AI Filing Summary

Kezar Life Sciences, Inc. submitted a Form 25 notification reflecting the removal/withdrawal of its common stock from listing and registration on the Nasdaq Stock Market LLC. The filing states the Exchange and the Issuer each complied with the procedures under 17 CFR 240.12d2-2.

Insights

Securities Compliance Analyst

Routine listing withdrawal certified by Nasdaq and the issuer.

The filing is a procedural notice under the Exchange Act notifying removal of common stock from Nasdaq; it cites the Exchange's compliance with 17 CFR 240.12d2-2. This is an administrative step recording delisting/withdrawal rather than operational or financial results.

Timing and next-step details are not provided in the excerpt; subsequent filings and exchange notices may state effective dates and any transfer actions.

Key Figures

Commission File Number: 001-38542 Regulation cited: 17 CFR 240.12d2-2(a)(1)-(4) Regulation cited (procedural): 17 CFR 240.12d-2(c) +2 more

5 metrics

Commission File Number 001-38542 Cover citation on Form 25

Regulation cited 17 CFR 240.12d2-2(a)(1)-(4) Rules governing removal/withdrawal procedures

Regulation cited (procedural) 17 CFR 240.12d-2(c) Issuer compliance for voluntary withdrawal

Address zip code 94080 Issuer principal executive office address

Form expiration note Expires: March 31, 2018 Form header expiration date

Key Terms

Form 25, 12(b) withdrawal, 17 CFR 240.12d2-2

3 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

12(b) withdrawal regulatory

"REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b)"

17 CFR 240.12d2-2 regulatory

"Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied"

A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Kezar Life Sciences (KZR) Form 25 mean?

It notifies the removal/withdrawal of KZR's common stock from Nasdaq listing under Form 25. The filing certifies that Nasdaq and the issuer complied with 17 CFR 240.12d2-2 procedures required for delisting or withdrawal.

Who certified the delisting on the Form 25 for KZR?

Nasdaq Stock Market LLC certified the Form 25 filing on its behalf. The filing states the Exchange has reasonable grounds and complied with the rules under 17 CFR 240.12d2-2 when striking the class from listing.

Which class of securities did KZR remove from Nasdaq?

The filing identifies the company's common stock as the class of securities removed from listing and/or registration on the Nasdaq Stock Market LLC, per the Form 25 notification language.

Does the Form 25 excerpt state when the delisting becomes effective?

The provided excerpt does not state an effective delisting date. The Form 25 certifies compliance with procedures; any effective date would appear in additional exchange or issuer disclosures.

What regulatory citations appear on KZR's Form 25?

The excerpt cites 17 CFR 240.12d2-2(a)(1), (a)(2), (a)(3), (a)(4), and the governing 12d2-2(b)/12d-2(c) provisions regarding withdrawal and exchange procedures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/11/2026 - 10:46 AM Learn about SEC filing dates

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-38542

Issuer:	Kezar Life Sciences, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	4000 Shoreline Court, Suite 300
	South San Francisco	CALIFORNIA	94080
Telephone number:					(650) 822-5612

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

common stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-05-11	By	Tara Petta		AVP
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.